MAY DEE GEMILO: Open Payments
NPI 1639645674 · EVERETT, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,351 in 79 payments from 13 companies in 2025. Trend: 2023 $352 · 2024 $2,060 · 2025 $1,351
Food & beverage: $1,351
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $194 |
| ABBVIE INC. | 12 | $178 |
| Vanda Pharmaceuticals Inc. | 9 | $157 |
| Teva Pharmaceuticals USA, Inc. | 11 | $156 |
| Supernus Pharmaceuticals, Inc. | 9 | $140 |
| Alkermes, Inc. | 5 | $122 |
| E.R. Squibb & Sons, L.L.C. | 4 | $93 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Axsome Therapeutics, Inc. | 4 | $71 |
| Janssen Pharmaceuticals, Inc | 3 | $59 |
Products named: CAPLYTA, VRAYLAR, FANAPT, Qelbree, AUSTEDO XR, ARISTADA, COBENFY, REXULTI.
Industry payments across WA — which companies pay providers there.
